{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:37:53Z","timestamp":1768808273853,"version":"3.49.0"},"reference-count":33,"publisher":"EDP Sciences","issue":"12","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>La prise en charge th\u00e9rapeutique de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA) est un enjeu majeur de sant\u00e9 publique. L\u2019une de ses deux formes tardives, la DMLA n\u00e9ovasculaire, est actuellement trait\u00e9e par injection intravitr\u00e9enne de mol\u00e9cules anti-angiog\u00e9niques. Bien qu\u2019elle soit tr\u00e8s efficace pour traiter les atteintes du segment post\u00e9rieur de l\u2019\u0153il, la voie intravitr\u00e9enne n\u2019est pas une option id\u00e9ale pour la prise en charge au long cours d\u2019une maladie chronique telle que la DMLA. L\u2019administration topique de mol\u00e9cules actives contre cette maladie, plus confortable pour le patient et moins co\u00fbteuse pour la soci\u00e9t\u00e9, repr\u00e9sente un vrai d\u00e9fi.<\/jats:p>","DOI":"10.1051\/medsci\/2023177","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T09:08:04Z","timestamp":1702890484000},"page":"958-966","source":"Crossref","is-referenced-by-count":2,"title":["Traitement topique de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge"],"prefix":"10.1051","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6475-7657","authenticated-orcid":false,"given":"Mitta","family":"Pierre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Lamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Benhida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Demange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Charrueau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000524942","volume":"65","author":"Garcia-Garcia","year":"2022","journal-title":"Ophthalmic Res"},{"key":"R3","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12886-022-02602-9","volume":"22","author":"Fonteh","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"R5","first-page":"353","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"R6","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1051\/medsci\/2020159","volume":"36","author":"Roubeix","year":"2020","journal-title":"Med Sci (Paris)"},{"key":"R7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","volume":"123","author":"Davis","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R9","first-page":"S2","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"R10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"R11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1051\/medsci\/200925121105","volume":"25","author":"Leveziel","year":"2009","journal-title":"Med Sci (Paris)"},{"key":"R12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.clinthera.2021.08.011","volume":"43","author":"Schultz","year":"2021","journal-title":"Clin Ther"},{"key":"R13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3109\/08820538.2010.541318","volume":"26","author":"Doshi","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"R14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/11206721211001716","volume":"32","author":"Pina Mar\u00edn","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1055\/a-1473-5713","volume":"239","author":"Hollaus","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"key":"R16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/13696998.2021.1971416","volume":"24","author":"Korobelnik","year":"2021","journal-title":"J Med Econom"},{"key":"R17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"Boyle","year":"2018","journal-title":"Psychology, Health & Medicine"},{"key":"R18","first-page":"CD012208","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"R20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jconrel.2020.10.025","volume":"328","author":"Singh","year":"2020","journal-title":"J Control Release"},{"key":"R21","doi-asserted-by":"crossref","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci Adv"},{"key":"R22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2018.05.020","volume":"281","author":"Xu","year":"2018","journal-title":"J Control Release"},{"key":"R23","unstructured":"National Institutes of Health Clinical Center (CC). A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration. clinicaltrials.gov, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00306488."},{"key":"R24","unstructured":"Alcon Research. The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00890097."},{"key":"R25","unstructured":"MacuCLEAR, Inc., Phase II\/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 1.0% BID in the Treatment of Non-exudative Age-Related Macular Degeneration. clinicaltrials.gov, 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02127463."},{"key":"R26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.oret.2022.08.003","volume":"7","author":"Vogl","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R27","unstructured":"CoMentis. A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab). clinicaltrials.gov, 2010. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00607750."},{"key":"R28","unstructured":"GlaxoSmithKline. MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. clinicaltrials.gov, 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01134055."},{"key":"R29","unstructured":"Bayer. A Combined Phase IIa \/ IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-na\u00efve Subjects With Neovascular Age Related Macular Degeneration. clinicaltrials.gov, 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02222207."},{"key":"R30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ajo.2022.02.019","volume":"239","author":"Poor","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R31","unstructured":"Ohr Pharmaceutical Inc. OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02727881."},{"key":"R32","unstructured":"PanOptica, Inc. A Randomized, Double Masked, Uncontrolled, Multicenter Phase I\/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Na\u00efve Participants With Neovascular Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03479372."},{"key":"R33","unstructured":"Chaney P. PAN-90806: once-daily topical anti-VEGF eye drop for wet AMD and other neovascular eye disease. Ophthalmology Innovation Summit, San Francisco 2019.  https:\/\/www.panopticapharma.com\/wp-content\/uploads\/2019\/10\/PAN-90806-Data-at-OIS@AAO.pdf."}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.medecinesciences.org\/10.1051\/medsci\/2023177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T09:11:15Z","timestamp":1702890675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medecinesciences.org\/10.1051\/medsci\/2023177"}},"subtitle":["O\u00f9 en sommes-nous ?"],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":33,"journal-issue":{"issue":"12"},"alternative-id":["msc230167"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/2023177","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}